Papillary thyroid microcarcinoma: optimal management versus overtreatment.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
22
10
2019
medline:
18
9
2020
entrez:
22
10
2019
Statut:
ppublish
Résumé
The treatment of small, low-risk papillary thyroid carcinoma has undergone a paradigm shift, with many tumors now initially treated with active surveillance rather than upfront surgery. Further studies on patients enrolled in active surveillance have refined our knowledge of the clinical behavior of papillary thyroid microcarcinomas. This article summarizes the major conclusions of landmark trials that launched active surveillance as a viable treatment option for selected patients. We discuss patient factors such as age and tumor size, the assessment of candidates for active surveillance, barriers to acceptance of active surveillance, quality of life issues, and economic considerations. Active Surveillance is a viable first-line treatment option for select papillary microcarcinomas.
Identifiants
pubmed: 31633497
doi: 10.1097/CCO.0000000000000595
pii: 00001622-202001000-00002
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-6Références
Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. Jama 2017; 317:1338–1348.
Ito Y, Miyauchi A, Kihara M, et al. Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg 2018; 42:615–622.
Brito JP, Al Nofal A, Montori VM, et al. The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in Olmsted County, Minnesota during 1935 through 2012. Thyroid 2015; 25:999–1007.
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140:317–322.
Ho AS, Davies L, Nixon IJ, et al. Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. Cancer 2015; 121:1793–1799.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Force USPSTScreening for thyroid cancer: US preventive services task force recommendation statement. Jama 2017; 317:1882–1887.
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016; 2:1023–1029.
Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 2017; 27:751–756.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26:1–133.
Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010; 34:28–35.
Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014; 24:27–34.
Oda H, Miyauchi A, Ito Y, et al. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid 2016; 26:150–155.
Ho AS, Chen I, Melany M, Sacks WL. Evolving management considerations in active surveillance for micropapillary thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes 2018; 25:353–359.
Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 2017; 143:1015–1020.
Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010; 34:1222–1231.
Kwon H, Oh HS, Kim M, et al. Active surveillance for patients with papillary thyroid microcarcinoma: a single center's experience in Korea. J Clin Endocrinol Metab 2017; 102:1917–1925.
Oh HS, Ha J, Kim HI, et al. Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea. Thyroid 2018; 28:1587–1594.
https://clinicaltrials.gov/ct2/show/NCT02609685. [Accessed 10 June 2019]
Lowenstein LM, Basourakos SP, Williams MD, et al. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nat Rev Clin Oncol 2019; 16:168–184.
Griffin A, Brito JP, Bahl M, Hoang JK. Applying criteria of active surveillance to low-risk papillary thyroid cancer over a decade: how many surgeries and complications can be avoided? Thyroid 2017; 27:518–523.
Miyauchi A, Kudo T, Ito Y, et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery 2018; 163:48–52.
Miyauchi A, Ito Y, Oda H. Insights into the management of papillary microcarcinoma of the thyroid. Thyroid 2018; 28:23–31.
Ho AS, Luu M, Zalt C, et al. Mortality risk of nonoperative papillary thyroid carcinoma: a corollary for active surveillance. Thyroid 2019; doi: 10.1089/thy.2019.0060. [Epub ahead of print].
doi: 10.1089/thy.2019.0060.
Khokhar MT, Day KM, Sangal RB, et al. Preoperative high-resolution ultrasound for the assessment of malignant central compartment lymph nodes in papillary thyroid cancer. Thyroid 2015; 25:1351–1354.
Kim HI, Jang HW, Ahn HS, et al. High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J Clin Endocrinol Metab 2018; 103:446–451.
Ho AS, Daskivich TJ, Sacks WL, Zumsteg ZS. Parallels between low-risk prostate cancer and thyroid cancer: a review. JAMA Oncol 2019; 5:556–564.
Nickel B, Brito JP, Moynihan R, et al. Patients’ experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study. BMC Cancer 2018; 18:242.
Nickel B, Brito JP, Barratt A, et al. Clinicians’ views on management and terminology for papillary thyroid microcarcinoma: a qualitative study. Thyroid 2017; 27:661–671.
Cho SJ, Suh CH, Baek JH, et al. Active surveillance for small papillary thyroid cancer: a systematic review and meta-analysis. Thyroid 2019; doi: 10.1089/thy.2019.0159. [Epub ahead of print].
doi: 10.1089/thy.2019.0159.
Grant EG, Tessler FN, Hoang JK, et al. Thyroid ultrasound reporting lexicon: white paper of the ACR thyroid imaging, reporting and data system (TIRADS) committee. J Am Coll Radiol 2015; 12:1272–1279.
Aschebrook-Kilfoy B, James B, Nagar S, et al. Risk factors for decreased quality of life in thyroid cancer survivors: initial findings from the North American thyroid cancer survivorship study. Thyroid 2015; 25:1313–1321.
Jeon MJ, Lee YM, Sung TY, et al. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: a cross-sectional study. Thyroid 2019; 29:956–962.
Davies L, Roman BR, Fukushima M, et al. Patient experience of thyroid cancer active surveillance in Japan. JAMA Otolaryngol Head Neck Surg 2019; 145:363–370.
White C, Weinstein MC, Fingeret AL, et al. Is less more? a microsimulation model comparing cost-effectiveness of the revised American Thyroid Association's 2015 to 2009 Guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer. Ann Surg 2018; doi: 10.1097/SLA.0000000000003074. [Epub ahead of print].
doi: 10.1097/sla.0000000000003074.
Venkatesh S, Pasternak JD, Beninato T, et al. Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer. Surgery 2017; 161:116–126.
Lang BH, Wong CK. A cost-effectiveness comparison between early surgery and nonsurgical approach for incidental papillary thyroid microcarcinoma. Eur J Endocrinol 2015; 173:367–375.
Oda H, Miyauchi A, Ito Y, et al. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr J 2017; 64:59–64.